Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations

Simply Wall St

November 02, 2024

Blueprint Medicines (NASDAQ:BPMC) Third Quarter 2024 Results

Key Financial Results

Revenue: US$128.2m (up 127% from 3Q 2023).
Net loss: US$56.3m (loss narrowed by 58% from 3Q 2023).
US$0.89 loss per share (improved from US$2.20 loss in 3Q 2023).

earnings-and-revenue-growth — NasdaqGS:BPMC Earnings and Revenue Growth November 2nd 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Blueprint Medicines EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 8.4%.

Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 10.0% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 1 warning sign for Blueprint Medicines that you should be aware of.

Mobile Infrastructure for Defense and Disaster

The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.

Get the investor briefing before the next round of contracts

Valuation is complex, but we're here to simplify it.

Discover if Blueprint Medicines might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.